RecruitMe Clinical Trial

A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating NEOadjuvant immunotherapy Based Combinations in Patients with Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC)
A study of Neoadjuvant Immunotherapy Combinations in Patients with Pancreatic Ductal Adenocarcinoma (NEOiPANC)
Sponsor:Genentech
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS1908
U.S. Government ID:NCT03979066
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to determine if treatment with atezolizumab and PEGylated Recombinant Human Hyaluronidase (PEGPH20), given before and after surgery, in addition to chemotherapy, is safe and if it can further increase the chance of cure. Approximately 40 patients will be asked to participate in this study, 20 randomized (chance of flipping a coin) to receive atezolizumab, and 20 randomized (chance of flipping a coin) to receive the combination of atezolizumab plus PEGPH20.

Do You Qualify?
Are you 18 years of age or older?YesNo
Do you have a diagnosis of pancreatic adenocarcinoma?YesNo
Have you had any prior surgical, systemic, or radiotherapy for pancreatic adenocarcinoma?YesNo
Submit
Cancel
Investigator
Gulam Manji, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162